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Type 2 diabetes mellitus (DM) may lead not only to early development of accelerated coronary artery disease (CAD) but also to cardiomyopathy (CMP), both of which confer an excess morbidity and mortality in these patients. 1 -3 As there is a continuous increase in the prevalence of DM in industrialized nations, it raises a considerable public health concern. Subclinical markers of early functional and structural vasculopathy such as an impairment of coronary circulatory function, 4 increased carotid intima-media thickeness (IMT), 5 and coronary artery calcification 6 have all been demonstrated independently to predict the initiation and/or progression of CAD and subsequent cardiovascular events. More recently, cardiovascular magnetic resonance (CMR) assessment of increased extracellular volume (ECV) fraction of the left ventricle, which can be assumed to probe features of adverse myocardial remodelling, predicted mortality and heart failure-related events in an independent fashion in a general cardiovascular risk cohort. 7 It is important to consider that, despite the standard use of preventive antidiabetic medication, DM is still associated with a greater coronary atherosclerotic burden, accelerated CAD progression, and CMP manifestation than in those individuals with cardiovascular risk but without a hyperglycaemic state. 3, 8 This emphasizes the necessity for additional diagnostic and medical therapeutic strategies aiming to prevent or inhibit the progression of diabetes-induced vasculopathy and/or CMP and, thereby, to improve cardiovascular outcome. Nowadays, CMR has evolved as a unique imaging tool to identify and characterize subclinical and clinically manifest alterations of the myocardial tissue. CMR in concert with intravenous use of gadolinium is commonly applied for determining myocardial perfusion with the first-pass technique as well as for the assessment of myocardial necrosis, oedema, fibrosis, and infiltrative processes with late gadolinium enhancement (LGE) image acquisition. 9 Under normal circumstances, gadolinium is limited to the extracellular space. Alterations of myocardial tissue structure, however, due to myocardial infarction, oedema, fibrosis, and infiltrative disease leads to an expansion of the extracellular space. This causes a larger amount of gadolinium to diffuse and to accumulate in the altered myocardial tissue. The accumulation of gadolinium in concert with its slower wash-out rate as compared with normal myocardium manifests in a bright signal on delayed T1-weighted CMR images. Although LGE imaging with CMR excellently distinguishes abnormally altered from normal myocardial tissue, uniform diffuse processes such as the development of interstitial fibrosis in DM or hypertensive patients may remain undetected. 9 For this purpose, CMR contrast imaging with T1 mapping has been developed to assess more diffuse processes involving the extracellular or interstitial myocardial space, which goes beyond the scope of conventional LGE imaging ( Figure 1 ). T1 mapping is performed by assessing the partition coefficient (l) for gadolinium contrast from pre-and post-contrast T1 measurements. The partition coefficient in concert with the blood haematocrit enables the ECV to be calculated.
pre-and post-gadolinium contrast.
Quantification of ECV has been demonstrated to parallel closely histological markers of collagen volume fraction (representing diffuse fibrosis) (r ¼ 0.69, P ¼ 0.013) in an animal model. 10 In addition, clinical validation of T1 mapping with CMR was performed in patients undergoing aortic valve replacement for aortic stenosis (n ¼ 18) or myectomy in hypertrophic cardiomyopathy (n ¼ 8).
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Also here, the ECV as determined with T1 mapping strongly correlated with histological fibrosis from biopsies (r ¼ 0.89, P , 0.001).
Conversely, it is important to be aware that expanded ECV determined from T1 mapping may not only represent diffuse interstitial fibrosis but it may also increase due to alterations of other components of the extracellular matrix such as non-collagenous proteins, fibroblasts, endothelial cells, vessels, oedema, and infiltrative diseases. 12 Wong and colleagues 13 now provide three types of novel informa-
tion. The authors demonstrate: (i) that DM is associated with increased ECV of the left ventricle; (ii) that ECV assessment identifies lower myocardial extracellular matrix expansion in DM individuals Editorial being treated with medication blocking the renin -angiotensinaldosterone system (RAAS); and (iii) that increased ECV is associated with mortality and/or incident hospitalization for heart failure in diabetic individuals. This analysis included 1176 consecutive patients referred for CMR without amyloidosis and other forms of infiltrative disease, hypertrophic cardiomyopathy, genetic disorders with distinct clinical characteristics, type 1 DM, and adult congenital heart disease. In order to maximize generalizability, the authors also included individuals with myocardial infarction. As myocardial infarction size can vary greatly, it was ascertained that ECV was measured specifically in remote non-infarcted myocardium, avoiding even the area at risk. It was found that DM patients (n ¼ 231) had higher median ECV than those with cardiovascular risks without diabetes (n ¼ 945): 30.2% vs. 28.1%, while a marked overlap was observed in the individual measurements of ECV. In the cross-sectional comparison, RAAS blockade was independently associated with lower ECV. Furthermore, over a median of 1.3 years, 38 diabetic individuals had events (21 incident hospitalizations for heart failure; 24 deaths), and, importantly, increased ECV was independently associated with these events ( hazard ratio 1.52, 95% confidence interval 1.21-1.89). As in a previous investigation, 7 ECV was calculated from preand post-contrast T1 measurements applying an ECG-gated singleshot modified look locker inversion recovery (MOLLI) technique. This technique has been validated previously with a high reproducibility of ECV measurements. 11, 12 ECV estimates were derived from basal and mid ventricular short axis slices to yield the final value, while apical slices of the left ventricle were excluded from analysis to reduce error related to partial volume averaging. This investigation constitutes the first report of an association between measurements of ECV and clinical outcome, defined as mortality and/or incident hospitalization for heart failure. It extends previous observations in a non-specific cohort of 793 consecutive patients with cardiovascular risk referred for CMR 7 to a specific population of DM patients. 14 Notably, those DM individuals who were on RAAS blockade had less ECV than those without. These observations may indeed suggest that CMR assessment of ECV may be a promising tool for an optimized identification and characterization of subclinical and clinically manifest diabetic CMP. The study opens up a new avenue for assessment and monitoring of intensified therapeutic responses in individual DM patients. Conversely, the median follow-up period was only 1.3 years and the number of adverse cardiac events limited to 21 incident hospitalizations for heart failure, which can be seen as a relatively weak endpoint, in addition to 24 deaths in 231 DM patients. Compared with cardiovascular risk patients without DM, DM patients were substantially older, had more arterial hypertension, dyslipidaemia, suspicion for CAD, lower left ventricular ejection fraction, and more advanced left ventricular remodelling, as well as more frequent hospitalization. Overall, the study may be relatively underpowered to adjust the multivariable models fully in a high cardiovascular risk DM population. In addition, risk adjustment may have been limited by unaccounted, potentially unmeasured confounding factors. Larger studies with longer followup, therefore, are desirable to investigate further the tightness of the described association between CMR-determined increased ECV and adverse cardiac events, in particular in subclinical DM patients with normal cardiac function. Such comprehensive investigations are clearly needed for a more precise assessment of the incremental prognostic value of increased ECV and to define ECV thresholds to optimize cardiac risk prediction in subclinical DM. Yet, defining ECV thresholds to optimize cardiac risk prediction seems to remain a challenge as there is a significant overlap in ECV between DM and non-DM patients in the investigation of Wong et al., 14 as well as in cardiovascular risk individuals and healthy volunteers. 7 Another limitation of the current investigation may be seen in the cross-sectional evaluation of the effects of RAAS blockade on ECV in DM. Longitudinal follow-up studies evaluating the ECV before and after RAAS blockade certainly are needed to provide more definitive proof of causality and treatment success. Further, no information about the mechanisms of death is provided. Thus, it remains uncertain how many deaths were truly related to diabetesinduced CMP or rather to no-cardiac but diabetes-related comorbidities. The current study therefore does not allow definite conclusions to be draw on the association between ECV expansion and specific cardiac causes of death. In addition, information on other cardiac outcomes, such as myocardial infarction and coronary revascularization, related to myocardial ECV expansion in DM would be desirable. Overall, the study of Wong et al. 14 represents an important first step in the identification and characterization of extracellular matrix expansion with cardiac CMR and T1 mapping (Figure 1) , which carries important diagnostic and prognostic information in DM. 9 These observations stress the notion of a pathophysiological link between increased ECV and adverse remodelling and, ultimately, the transition to clinically manifest diabetic CMP. This CMR-guided approach to identify increased ECV holds promise ultimately to allow earlier and more precise identification and characterization of diabetic CMP, and the assessment and monitoring of the therapeutic response in the individual DM patient. However, whether such image-guided and personalized medical intervention striving to prevent or delay the initiation and/or progression of left ventricular remodelling will ultimately manifest in improved clinical outcome remains to be clinically evaluated.
